Exenatide: difference between revisions
Diff·revision 21 → 22·06:30, 22 Sep 2025
Difference between revision 21 and revision 22 of Exenatide. 2 lines changed; the page grew by 223 bytes.
| Revision 21 — 10:09, 28 Aug 2025 CategoryBot (talk) bot: sort category members 5,531 bytes ±0 | Revision 22 — 06:30, 22 Sep 2025 CagriCass (talk) add the excipient list from the labelling 5,754 bytes +223 | ||
|---|---|---|---|
| 40 | That result is worth noting whenever a cardiovascular benefit is described as a class effect: within the same class, [[LEADER trial|LEADER]] and [[SELECT trial|SELECT]] were positive, EXSCEL was neutral, and the outcome trial of lixisenatide was neutral. Whether the differences reflect molecule, dose, population or duration is unresolved.{{r|holman2017}} | 40 | That result is worth noting whenever a cardiovascular benefit is described as a class effect: within the same class, [[LEADER trial|LEADER]] and [[SELECT trial|SELECT]] were positive, EXSCEL was neutral, and the outcome trial of lixisenatide was neutral. Whether the differences reflect molecule, dose, population or duration is unresolved.{{r|holman2017}} |
| 41 | 41 | ||
| + | 42 | Exenatide retains some use where a short-acting agent is specifically wanted, since its effect on [[Gastric emptying|gastric emptying]] does not attenuate in the way that a continuously present long-acting agonist's does. | |
| + | 43 | ||
| 42 | == References == | 44 | == References == |
| 43 | {{reflist}} | 45 | {{reflist}} |